ZHEJIANG JUTAI PHARM
GenericsZHEJIANG JUTAI PHARM is a generic drug manufacturer focused on Neurology.
ZHEJIANG JUTAI PHARM's Key Drugs
ZHEJIANG JUTAI PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ZHEJIANG JUTAI PHARM's Recent FDA Approvals
New NDA/BLA approvals for ZHEJIANG JUTAI PHARM over the last two years — novel drugs only, excluding generics and label supplements.
ZHEJIANG JUTAI PHARM's Therapeutic Areas
ZHEJIANG JUTAI PHARM's approved drugs and pipeline span 1 therapeutic area, led by Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ZHEJIANG JUTAI PHARM's Top Competitors
ZHEJIANG JUTAI PHARM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ZHEJIANG JUTAI PHARM Pipeline Snapshot
Active clinical trials for ZHEJIANG JUTAI PHARM across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2019-09-05
- Latest
- 2025-07-10
- Applications
- 3